Thrivent Financial for Lutherans Takes $712,000 Position in Humacyte, Inc. (NASDAQ:HUMA)

Thrivent Financial for Lutherans bought a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) in the third quarter, Holdings Channel reports. The firm bought 130,894 shares of the company’s stock, valued at approximately $712,000.

Other institutional investors have also made changes to their positions in the company. Renaissance Technologies LLC increased its stake in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Virtu Financial LLC acquired a new position in Humacyte during the first quarter worth $197,000. Vanguard Group Inc. grew its holdings in shares of Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after acquiring an additional 896,415 shares in the last quarter. Millennium Management LLC increased its position in shares of Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after acquiring an additional 1,334,641 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after purchasing an additional 97,931 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 157,704 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $5.42, for a total value of $854,755.68. Following the completion of the sale, the chief executive officer now owns 3,519,558 shares in the company, valued at approximately $19,076,004.36. This trade represents a 4.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,662,886 shares of company stock worth $7,489,538 in the last ninety days. Corporate insiders own 11.20% of the company’s stock.

Analysts Set New Price Targets

HUMA has been the subject of several research analyst reports. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Humacyte in a research report on Wednesday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Humacyte currently has a consensus rating of “Buy” and an average target price of $13.00.

Humacyte Stock Down 4.5 %

Shares of NASDAQ HUMA opened at $4.25 on Wednesday. The firm has a market cap of $534.91 million, a PE ratio of -3.17 and a beta of 1.38. Humacyte, Inc. has a 12-month low of $2.45 and a 12-month high of $9.97. The company’s fifty day simple moving average is $5.17 and its 200 day simple moving average is $6.13. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.